Drug Profile


Alternative Names: Atorvastatin/BR-A 657; Fimasartan/atorvastatin

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boryung Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Hypercholesterolaemia; Hypertension

Most Recent Events

  • 09 Feb 2017 Boryung Pharmaceutical initiates a phase I trial for Hypertension and Hypercholesterolaemia in South Korea (NCT02994745)
  • 20 Dec 2016 Boryung Pharmaceutical plans a phase I trial for Hypertension and Hypercholesterolaemia in South Korea (NCT02994745)
  • 01 Oct 2015 Boryung Pharmaceutical completes a phase I trial in Hypertension (In volunteers) and Hypercholesterolaemia (In volunteers) in South Korea (PO) (NCT02566187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top